Skip to content
Search

Latest Stories

New Zealand to tour Pakistan twice next season

NEW ZEALAND will tour Pakistan twice next season, including once to compensate for abandoning their tour earlier this year, the cricket boards of both countries said on Monday (20).

New Zealand had abandoned their tour in September citing a security threat, a decision which came as a massive blow to Pakistan's hopes of staging regular international cricket and infuriated the Pakistan board (PCB).


However, PCB chairman Ramiz Raja and his New Zealand counterpart Martin Snedden met in Dubai last month to build bridges between the boards.

New Zealand will tour Pakistan in December 2022-January 2023 to play two Tests and three one-day internationals before returning in April for five ODIs and a the same number of T20 Internationals.

"Our respective chairmen ... had very fruitful and constructive discussions while in Dubai, further strengthening the bond between the two organisations," New Zealand Cricket chief executive David White said in a statement.

"It’s good to be going back."

The exact dates of the matches would be finalised later.

"I am pleased with the outcomes of our discussions and negotiations, and thank Martin Snedden and his board for their understanding and support," Raja said in a statement.

"This reflects the strong, cordial and historic relations the two boards have and reconfirms Pakistan’s status as an important member of the cricket fraternity."

Raja had earlier alleged that Pakistan had been "used and binned" by the "Western Bloc" after England immediately followed New Zealand's lead by calling off their tour of the country.

England have since assured Pakistan they will visit for a full series in 2022.

(Reuters)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less